Lineage Cell Therapeutics Inc (LCTX)

[DeepDive]

Unsure, immaterial.

What these distributions do is to make the valuation of BTX less complicated and more understandable to the investing community.

Each time BTX's holding goes below 50%, the position is registered on the balance sheet as an asset (market value). above - the subsidiary needs to be consolidated which muddles the picture and hides the real value.

The main catalysts now are Renevia, the blood test (Oncocyte) and later, Opragen.

2018 will be a year with revenue growth when the market will realize the value and scope of BTX's (and Subs) technology and potential earning power.

Nothing will happen next month, but that's fine.

Patient investors who understand the vast platform this business is developing get a chance to build a position sub 2.5$ from time to time and will realize massive returns in the coming years.

GL